Business Context and Reporting Period
This Form 8-K filing by Quantum Cyber N.V. (formerly Mainz Biomed N.V.) covers events occurring on April 22, 2026. The company, incorporated in The Netherlands and trading on the Nasdaq Capital Market under the symbol QUCY, reported the completion of a significant private placement, a change in corporate control, a name change, and a complete restructuring of its Board of Directors.
Key Financial Metrics and Capital Structure
The filing details a two-closing private placement totaling $6 million in gross proceeds:
- First Closing (Feb 17, 2026): Issuance of Series A, B, and C Preferred Shares for $3 million.
- Second Closing (April 22, 2026): Issuance of Series D and E Preferred Shares for an additional $3 million (pre-paid in March 2026).
- Dilution Impact: The Second Closing Shares represented over 90% of the company's issued and outstanding ordinary shares on a fully diluted basis at issuance.
- Authorized Capital: Authorized ordinary shares increased from 45 million to 900 million; authorized preferred shares increased from 5 million to 100 million.
The filing does not provide specific revenue, profit, cash flow, or debt metrics for the reporting period.
Material Changes Versus Prior Period
- Change in Control: David E. Lazar became the controlling shareholder, holding over 95% of the voting rights on a fully diluted basis following the issuance of the Second Closing Shares.
- Corporate Name: The company officially changed its name from "Mainz Biomed N.V." to "Quantum Cyber N.V."
- Board Composition: Four directors (Guido Baechler, Dr. Heiner Dreismann, Hans Hekland, and Greggory Tibbits) resigned. Two new directors (David Natan and Avraham Ben-Tzvi) were appointed. The board now consists of David Lazar, Robert Liscouski, David Natan, and Avraham Ben-Tzvi.
- Executive Leadership: Guido Baechler resigned as Co-Chief Executive Officer.
- Shareholder Approval: An Extraordinary General Meeting approved all proposals, including the issuance of shares, the name change, and the appointment of new directors.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, revenue outlook, or management commentary regarding future financial performance. The primary risks and contingencies identified are:
- Concentration of Ownership: A single shareholder (David E. Lazar) now controls over 95% of voting rights, which may limit the influence of other shareholders.
- Significant Dilution: The issuance of Series D and E shares resulted in massive dilution for existing shareholders, with the new shares representing over 90% of the fully diluted share count.
- Leadership Transition: The resignation of the Co-CEO and the majority of the board indicates a significant shift in corporate strategy and governance.
Key Facts for Investor Verification
- Verify the exact conversion ratios and terms of the Series A through E Preferred Shares to understand the final dilution impact on ordinary shares.
- Confirm the current cash position and burn rate post-transaction, as the filing notes $6 million in proceeds but provides no balance sheet data.
- Review the strategic rationale for the name change from "Mainz Biomed" to "Quantum Cyber" to assess potential pivots in business operations.
- Monitor the appointment of a new CEO, as the Co-CEO resigned and no successor was explicitly named in this filing.
- Check for any subsequent filings regarding the specific use of the $6 million raised in the private placement.